Alzamend Neuro ALZN Cash Flow Statement (2020-2026)

NASDAQ ALZN
$1.78 -0.04 (-2.14%)
As of: Sep 30, 2026 · 12:33 PM EDT
Reported Financials

Alzamend Neuro Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jul 2026

Alzamend Neuro reported cash from operations of -$1.14M and free cash flow of -$1.14M for the quarter ended Jul 2026, up 51.8% year over year. This cash flow statement covers 25 quarters of results from Jul 2020 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jul2020 Oct2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026 Jul2026
Operating Activities
Net Income
-3.60M-2.57M-3.87M-3.04M-3.11M-5.43M-3.31M-3.53M-2.91M-2.66M-0.85M-0.97M-1.36M-1.04M-1.14M-2.70M-1.00M-2.20M-2.87M-3.03M
Depreciation and Depletion
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.03M0.03M0.03M0.03M0.03M
Share-based Compensation
1.28M1.13M1.26M0.87M0.72M1.51M0.49M0.37M0.32M0.19M0.08M0.08M0.08M0.08M0.08M0.04M0.03M0.01M0.62M0.08M
Cash from Operations
-2.05M-1.78M-1.56M-2.54M-2.34M-1.81M-2.24M-3.30M-1.51M-2.03M-1.43M-1.06M-3.40M-1.42M-0.69M-2.36M-1.17M-1.74M-2.80M-1.14M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.03M0.03M0.03M0.03M0.03M
Change in Working Capital
Change in Account Payables
-0.02M-0.61M0.76M-0.14M-0.38M1.99M0.23M
Change in Accured Expenses
-0.14M-0.38M1.99M0.23M-0.13M0.93M0.16M-0.90M-0.04M-1.63M-0.62M-0.00M0.35M-0.27M1.14M-0.51M1.39M
Other Working Capital Changes
-0.27M-0.29M-0.29M0.24M-0.18M0.14M-0.10M0.27M-0.14M-0.27M-0.23M0.14M0.45M-0.08M-0.36M0.08M-0.04M0.71M0.07M-0.39M
Investing Activities
Capital Expenditures
0.15M0.09M0.21M
Cash from Investing Activities
-0.15M-0.09M-0.21M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Issuances
Change in Capital Stock
Net Preferred Shares Issued and Repurchased
1.96M5.12M
Net Equity Issued and Repurchased
0.96M0.27M1.96M-0.79M0.69M5.87M4.04M7.35M
Misc.
Cash from Financing Activities
700.00400.003.94M2.11M1.52M1.96M6.30M0.69M1.49M4.04M0.79M8.02M
Change in Cash
-2.05M-1.78M2.27M-2.54M-2.34M-1.81M-2.23M-3.45M-1.50M0.08M0.09M0.82M2.90M-0.73M0.59M1.67M-1.17M-1.74M-2.00M6.88M
Free Cash Flow
-2.05M-1.78M-1.56M-2.54M-2.34M-1.81M-2.24M-3.45M-1.51M-2.03M-1.43M-1.15M-3.40M-1.42M-0.90M-2.36M-1.17M-1.74M-2.80M-1.14M
Net Cash Flow
-2.05M-1.78M2.38M-2.54M-2.34M-1.81M-2.24M-3.45M-1.51M0.08M0.09M0.82M2.90M-0.73M0.59M1.67M-1.17M-1.74M-2.00M6.88M

Alzamend Neuro Cash Flow Statement API

Pull Alzamend Neuro's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALZN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY